New insight into RASopathy-associated lymphatic defects

The RAS pathway is a cellular signaling pathway that regulates growth and development in humans. RASopathies are a group of diseases characterized by defects in RAS signaling.

Many patients with RASopathies present with defects in the lymphatic system, which removes excess fluid from tissues, absorbs fats from the digestive system, and transports immune cells.

To determine how alterations in the RAS pathway affect development of the lymphatic system, researchers at Yale University generated that expressed mutations associated with a RASopathy known as .

In this issue of the , Michael Simon and colleagues report that excess RAS pathway activation triggers increased activity of a protein known as ERK.

Mice with RASopathy-associated mutations exhibited lymphatic defects similar to those seen in humans, but the defects could be reversed by treatment with an ERK inhibitor.

These findings demonstrate that excessive ERK activation underlies lymphatic defects in RASopathies and suggest that ERK inhibition could be a useful therapeutic strategy.

More information: Endothelial ERK signaling controls lymphatic fate specification, Journal of Clinical Investigation, doi:10.1172/JCI63034

add to favorites email to friend print save as pdf

Related Stories

Lack of specific gene plays role in autism

Feb 09, 2009

It is estimated that three to six out of every 1,000 children in the United States have autism - and the number of diagnosed cases is rising. Autism is one of a group of series developmental problems called autism spectrum ...

Combination therapies for drug-resistant cancers

Oct 10, 2011

Some cancers can be effectively treated with drugs inhibiting proteins known as receptor tyrosine kinases, but not those cancers caused by mutations in the KRAS gene. A team of researchers led by Jeffrey Engelman, at Massachusetts ...

Recommended for you

Ebola vaccine promising in first human trials

2 hours ago

Researchers say they are one step closer to developing an Ebola vaccine, with a Phase 1 trial showing promising results, but it will be months at the earliest before it can be used in the field.

At one month, US Ebola monitors finding no cases

5 hours ago

The U.S. program that requires weeks of monitoring for travelers from African countries with Ebola reaches the one-month mark Thursday. And so far, no cases of the disease have turned up.

EU calls for 5,000 doctors to fight Ebola

5 hours ago

The European Commission called for 5,000 doctors to be sent from EU states to combat west Africa's Ebola epidemic, a European source with knowledge of the matter said on Wednesday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.